Review: taking Ddavp and Miralax together


Summary

Drug interactions are reported among people who take Ddavp and Miralax together. This review analyzes the effectiveness and drug interactions between Ddavp and Miralax. It is created by eHealthMe based on reports of 60 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Ddavp

Ddavp has active ingredients of desmopressin acetate. It is often used in diabetes insipidus. (latest outcomes from Ddavp 1,702 users)

Miralax

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. (latest outcomes from Miralax 27,403 users)

On Sep, 15, 2016

60 people who take Ddavp, Miralax are studied.


Number of reports submitted per year:

Ddavp and Miralax drug interactions.

Drug effectiveness over time:

Ddavp:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Miralax:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Ddavp:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 0 people)
Miralax:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Ddavp:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Miralax:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • cystitis
  • diverticulitis
  • gastritis
  • haemorrhoidal haemorrhage
  • lethargy
  • neuropathy peripheral
not specified:
  • constipation
  • fall
  • granulocytopenia
  • leukopenia
  • decreased appetite
  • diabetes insipidus
  • pyrexia
  • vomiting
  • pain
  • dehydration

Most common drug interactions by gender *:

female:
  • pyrexia
  • anaemia
  • neutropenia
  • pain
  • tremor
  • vomiting
  • hyperkalaemia
  • abdominal pain lower
  • anal abscess
  • anxiety
male:
  • vomiting
  • constipation
  • dehydration
  • pain
  • pyrexia
  • fall
  • granulocytopenia
  • leukopenia
  • decreased appetite
  • diabetes insipidus

Most common drug interactions by age *:

0-1:
  • constipation
  • decreased appetite
  • diabetes insipidus
  • hyponatraemia
  • muscle spasms
  • myoclonic epilepsy
  • pain
  • vomiting
  • dehydration
  • hypernatraemia
2-9:
  • convulsion
  • infection
  • pyrexia
  • weight decreased
  • anaemia
  • blood glucose decreased
  • cellulitis
  • cerebral cyst
  • dyspnoea
  • emotional distress
10-19:
  • parotitis
  • systemic lupus erythematosus
  • vomiting
  • nausea
  • dehydration
  • diarrhoea
  • renal failure
  • renal failure acute
  • abdominal pain lower
  • agitation
20-29:
  • drug withdrawal syndrome
  • hypertonia
  • implant site cellulitis
  • implant site discolouration
  • implant site erythema
  • implant site infection
  • implant site pruritus
  • implant site rash
  • implant site swelling
  • muscle spasticity
30-39:
  • granulocytopenia
  • asthenia
  • bipolar disorder
  • communication disorder
  • convulsion
  • fall
  • headache
  • memory impairment
  • menometrorrhagia
  • nausea
40-49:
  • anxiety
  • blood creatinine increased
  • complications of transplanted kidney
  • depression
  • diarrhoea
  • dizziness
  • flatulence
  • granulocytopenia
  • haematuria
  • haemoglobin decreased
50-59:
  • fall
  • metabolic encephalopathy
  • tibia fracture
  • toxic induced encephalopathy
  • cognitive disorder
  • disturbance in attention
  • hallucination
  • psychomotor retardation
  • somnolence
  • concomitant disease progression
60+:
  • dehydration
  • dysphagia
  • pyrexia
  • bradycardia
  • complications of transplanted kidney
  • conjunctivitis
  • cough
  • diarrhoea
  • hyperkalaemia
  • hypervolaemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Ddavp and Miralax?

Can you answer these questions?

More questions for: Ddavp, Miralax

You may be interested in these reviews

More reviews for: Ddavp, Miralax

On eHealthMe, Ddavp (desmopressin acetate) is often used to treat diabetes insipidus. Miralax (polyethylene glycol 3350) is often used to treat constipation. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.